Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.

Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, Woloszynska A.

Cell Death Differ. 2019 Jan 28. doi: 10.1038/s41418-019-0278-9. [Epub ahead of print]

PMID:
30692641
2.

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.

Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C.

BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x.

3.

Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival.

Amara CS, Ambati CR, Vantaku V, Badrajee Piyarathna DW, Donepudi SR, Ravi SS, Arnold JM, Putluri V, Chatta G, Guru KA, Badr H, Terris MK, Bollag RJ, Sreekumar A, Apolo AB, Putluri N.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):770-781. doi: 10.1158/1055-9965.EPI-18-0936. Epub 2019 Jan 14.

PMID:
30642841
4.

Identification of targets for prostate cancer immunotherapy.

Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C.

Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6.

PMID:
30614027
5.

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.

Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG.

Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7.

6.

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer.

Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, Wang J, Woloszynska-Read A.

Cell Death Dis. 2017 Dec 14;8(12):3217. doi: 10.1038/s41419-017-0024-5.

7.

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

Joseph RW, Chatta G, Vaishampayan U.

Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2. Review.

PMID:
28259541
8.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

9.

Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.

Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P.

Prostate. 2016 Sep;76(12):1095-105. doi: 10.1002/pros.23194. Epub 2016 May 16.

PMID:
27199259
10.

Spur cell hemolytic anemia in liver failure.

Murphy CH, Jain S, Sabath DE, Chatta GS, Hess JR.

Transfusion. 2016 Apr;56(4):787-8. doi: 10.1111/trf.13407. No abstract available.

PMID:
27079310
11.

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.

Soni A, Aspinall SL, Zhao X, Good CB, Cunningham FE, Chatta G, Passero V, Smith KJ.

Oncol Res. 2014;22(5-6):311-9. doi: 10.3727/096504015X14424348426152.

PMID:
26629943
12.

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.

Aspinall SL, Good CB, Zhao X, Cunningham FE, Heron BB, Geraci M, Passero V, Stone RA, Smith KJ, Rogers R, Shields J, Sartore M, Boyle DP, Giberti S, Szymanski J, Smith D, Ha A, Sessions J, Depcinski S, Fishco S, Molina I, Lepir T, Jean C, Cruz-Diaz L, Motta J, Calderon-Vargas R, Maland J, Keefe S, Tague M, Leone A, Glovack B, Kaplan B, Cosgriff S, Kaster L, Tonnu-Mihara I, Nguyen K, Carmichael J, Clifford L, Lu K, Chatta G.

BMC Cancer. 2015 Feb 18;15:62. doi: 10.1186/s12885-015-1038-y.

13.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

14.

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M.

J Transl Med. 2012 Aug 3;10:156. doi: 10.1186/1479-5876-10-156.

15.

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92. doi: 10.1038/pcan.2011.49. Epub 2011 Oct 18.

16.

Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.

Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, Kalinski P.

Prostate. 2011 Feb 1;71(2):125-33. doi: 10.1002/pros.21228. Epub 2010 Aug 17.

17.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR.

Urology. 2010 Oct;76(4):923-6. doi: 10.1016/j.urology.2010.04.025. Epub 2010 Jun 19.

18.

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A.

Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. doi: 10.1007/s00280-010-1283-3. Epub 2010 Mar 20.

19.

Cancer chemotherapy in the elderly patient.

Gillison TL, Chatta GS.

Oncology (Williston Park). 2010 Jan;24(1):76-85. Review.

20.

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.

Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, Trepicchio W, Cooper M, Karol M, von Moltke L, Neuwirth R, Egorin M, Chatta G.

Clin Ther. 2009;31 Pt 2:2444-58. doi: 10.1016/j.clinthera.2009.11.012.

PMID:
20110052
21.

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.

Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR.

Anticancer Drugs. 2009 Mar;20(3):179-84. doi: 10.1097/CAD.0b013e328325a867.

22.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR.

Clin Genitourin Cancer. 2009 Jan;7(1):43-50. doi: 10.3816/CGC.2009.n.008.

PMID:
19213668
23.

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.

J Urol. 2009 Mar;181(3):1104-13; discussion 1113. doi: 10.1016/j.juro.2008.11.026. Epub 2009 Jan 23.

24.

Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.

J Urol. 2008 Oct;180(4):1432-7; discussion 1437. doi: 10.1016/j.juro.2008.06.017. Epub 2008 Aug 16.

25.

A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.

Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM, Ivy SP, Belani CP.

Clin Cancer Res. 2008 Jun 1;14(11):3456-61. doi: 10.1158/1078-0432.CCR-07-5088.

26.

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN Jr.

Clin Genitourin Cancer. 2007 Dec;5(7):433-7. doi: 10.3816/CGC.2007.n.031.

PMID:
18272025
27.

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators.

Cancer. 2008 Jan 15;112(2):326-30.

28.

Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.

Aalamian-Matheis M, Chatta GS, Shurin MR, Huland E, Huland H, Shurin GV.

Adv Exp Med Biol. 2007;601:173-82.

PMID:
17713004
29.

Dynamic alteration of soluble serum biomarkers in healthy aging.

Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE.

Cytokine. 2007 Aug;39(2):123-9. Epub 2007 Aug 8.

PMID:
17689975
30.

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute.

J Clin Oncol. 2007 Jun 1;25(16):2218-24. Erratum in: J Clin Oncol. 2008 Jul 1;26(19): 3295.

PMID:
17538166
31.

Aging and the dendritic cell system: implications for cancer.

Shurin MR, Shurin GV, Chatta GS.

Crit Rev Oncol Hematol. 2007 Nov;64(2):90-105. Epub 2007 Apr 18. Review.

32.

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA.

J Urol. 2007 May;177(5):1777-81.

PMID:
17437819
33.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.

Clin Cancer Res. 2007 Mar 15;13(6):1769-74.

34.

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators.

J Clin Oncol. 2007 Feb 20;25(6):669-74.

PMID:
17308271
35.

Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL.

Cancer Metastasis Rev. 2006 Sep;25(3):333-56. Review.

PMID:
17029028
36.

High dose calcitriol may reduce thrombosis in cancer patients.

Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG.

Br J Haematol. 2006 Nov;135(3):392-4. Epub 2006 Sep 19.

PMID:
16984385
37.

Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides.

Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR.

J Immunol. 2005 Sep 1;175(5):3045-52.

38.

Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS, Shurin MR.

J Immunol. 2005 May 1;174(9):5490-8. Erratum in: J Immunol. 2006 Mar 15;176(6):3840. Ferris, Robert [corrected to Ferris, Robert L].

39.

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.

Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL.

J Urol. 2005 May;173(5):1567-71. Erratum in: J Urol. 2005 Aug;174(2):796. Sartor, Oliver [added]; Higano, Celestia S [added]; Petrylak, Daniel P [added] Chatta, Gerkamal [added].

PMID:
15821487
40.

Small rho GTPases regulate antigen presentation in dendritic cells.

Shurin GV, Tourkova IL, Chatta GS, Schmidt G, Wei S, Djeu JY, Shurin MR.

J Immunol. 2005 Mar 15;174(6):3394-400.

41.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC.

Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27.

PMID:
15723261
42.

Human renal cell carcinoma inhibits dendritic cell maturation and functions.

Song EY, Shurin MR, Tourkova IL, Chatta G, Shurin GV.

Urologe A. 2004 Sep;43 Suppl 3:S128-30. No abstract available.

PMID:
15150693
43.

Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis.

Balkir L, Tourkova IL, Makarenkova VP, Shurin GV, Robbins PD, Yin XM, Chatta G, Shurin MR.

J Gene Med. 2004 May;6(5):537-44.

PMID:
15133764
44.

Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors.

Tourkova IL, Yamabe K, Foster B, Chatta G, Perez L, Shurin GV, Shurin MR.

Prostate. 2004 May 1;59(2):203-13.

PMID:
15042620
45.

Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand.

Shurin GV, Chatta GS, Tourkova IL, Zorina TD, Esche C, Shurin MR.

Exp Gerontol. 2004 Mar;39(3):339-48.

PMID:
15036393
46.
47.

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.

Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR.

J Urol. 2003 Nov;170(5):2026-30.

PMID:
14532846
48.

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA, Crawford ED.

Urology. 2001 Jul;58(1):53-8.

PMID:
11445479
49.

Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.

Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ.

Clin Cancer Res. 2001 Mar;7(3 Suppl):917s-924s.

PMID:
11300492
50.

T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis.

Chen W, Chatta GS, Rubin WD, Clark JG, Hackman RC, Madtes DK, Ligitt DH, Kusunoki Y, Martin PJ, Cheever MA.

J Immunol. 1998 Jul 15;161(2):909-18.

Supplemental Content

Loading ...
Support Center